Abeona Therapeutics Company Profile (NASDAQ:ABEO)

About Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics logoAbeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company's lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $223.42 million
  • Outstanding Shares: 40,255,000
Average Prices:
  • 50 Day Moving Avg: $5.55
  • 200 Day Moving Avg: $5.44
  • 52 Week Range: $2.31 - $9.44
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.33
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $888,999.00
  • Price / Sales: 251.31
  • Book Value: $2.46 per share
  • Price / Book: 2.26
Profitability:
  • EBIDTA: ($23,060,000.00)
  • Net Margins: -2,029.60%
  • Return on Equity: -26.65%
  • Return on Assets: -22.54%
Debt:
  • Debt-to-Equity Ratio: 0.06%
  • Current Ratio: 4.91%
  • Quick Ratio: 4.91%
Misc:
  • Average Volume: 230,967 shs.
  • Beta: 1.79
  • Short Ratio: 16.42
 

Frequently Asked Questions for Abeona Therapeutics (NASDAQ:ABEO)

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) issued its earnings results on Thursday, May, 18th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. The firm earned $0.19 million during the quarter, compared to the consensus estimate of $0.28 million. Abeona Therapeutics had a negative net margin of 2,029.60% and a negative return on equity of 26.65%. View Abeona Therapeutics' Earnings History.

Where is Abeona Therapeutics' stock going? Where will Abeona Therapeutics' stock price be in 2017?

6 brokers have issued 12 month price targets for Abeona Therapeutics' stock. Their forecasts range from $11.00 to $21.00. On average, they expect Abeona Therapeutics' share price to reach $16.83 in the next year. View Analyst Ratings for Abeona Therapeutics.

What are analysts saying about Abeona Therapeutics stock?

Here are some recent quotes from research analysts about Abeona Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "At the ASGCT meeting in Washington D.C., Abeona announced initial 30-day data in two patients treated with a high dose of ABO-102." (5/12/2017)
  • 2. FBR & Co analysts commented, "On March 31, Abeona Therapeutics reported results for a year in which all clinical programs achieved important regulatory and clinical milestones. Most notably, 2016 culminated in the initiation of dosing in the high-dose cohort of Abeona’s Phase I/II trial with ABO-102 in children with Sanfilippo Syndrome Type A (MPS IIIA). We think this milestone is significant as it highlights ABO-102’s continued safety, its promising biopotency, as well as its designation for FDA Fast Track status for a rare pediatric disease, as well as for an orphan disease. It also supports our view that Abeona’s ability to rapidly advance therapies with high-value potential and short pathways to regulatory approval remains under-appreciated. We look next for a clinical update on the EB-101 Phase I study later this month, an update on the Phase I/II study with ABO-101 in MPS IIIB, as well as Abeona’s three other ongoing rare disease programs in the next three to six months to be positive catalysts for ABEO stock." (4/5/2017)
  • 3. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (3/14/2017)
  • 4. Maxim Group analysts commented, "Abeona announced that EB-101, gene therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), received orphan designation in Europe." (3/10/2017)
  • 5. Jefferies Group LLC analysts commented, "ABO-102 Ph1/2 longer follow-up data in MPS IIIA at WORLDSymposium showed continued reduction in CSF GAG at 6 mon (n=2), while urinary GAG reduction appeared to plateau. Early sign of neurocognitive benefits was shown at 6mon (measured by Leiter-3), which we see as encouraging. We see potentially further improvement with longer follow-up based on KOL feedback." (2/17/2017)

Who are some of Abeona Therapeutics' key competitors?

Who owns Abeona Therapeutics stock?

Abeona Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), Soros Fund Management LLC (2.23%), Highbridge Capital Management LLC (1.69%), Perceptive Advisors LLC (1.55%), Nexthera Capital LP (1.23%) and Kavi Asset Management LP (0.00%). Company insiders that own Abeona Therapeutics stock include Mark J Ahn and Todd Wider. View Institutional Ownership Trends for Abeona Therapeutics.

Who sold Abeona Therapeutics stock? Who is selling Abeona Therapeutics stock?

Abeona Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Nexthera Capital LP and Dimensional Fund Advisors LP. View Insider Buying and Selling for Abeona Therapeutics.

Who bought Abeona Therapeutics stock? Who is buying Abeona Therapeutics stock?

Abeona Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, Goldman Sachs Group Inc., Morgan Stanley, Vanguard Group Inc., Laurion Capital Management LP, Wellington Management Group LLP, Hikari Power Ltd and Segantii Capital Management Ltd. Company insiders that have bought Abeona Therapeutics stock in the last two years include Mark J Ahn and Todd Wider. View Insider Buying and Selling for Abeona Therapeutics.

How do I buy Abeona Therapeutics stock?

Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Abeona Therapeutics stock cost?

One share of Abeona Therapeutics stock can currently be purchased for approximately $5.55.

Analyst Ratings

Consensus Ratings for Abeona Therapeutics (NASDAQ:ABEO) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.83 (203.30% upside)

Analysts' Ratings History for Abeona Therapeutics (NASDAQ:ABEO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/26/2017FBR & CoReiterated RatingBuyN/AView Rating Details
5/25/2017Maxim GroupSet Price TargetBuy$14.00LowView Rating Details
5/12/2017Cantor FitzgeraldReiterated RatingBuy$21.00HighView Rating Details
4/26/2017Jefferies Group LLCReiterated RatingBuy$11.00MediumView Rating Details
2/6/2017HC WainwrightSet Price TargetBuy$20.00N/AView Rating Details
2/7/2017Rodman & RenshawReiterated RatingBuy$17.00 -> $20.00N/AView Rating Details
7/20/2015MLV & Co.Initiated CoverageBuy$15.00N/AView Rating Details
6/11/2015Roth CapitalInitiated CoverageBuy$16.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Abeona Therapeutics (NASDAQ:ABEO)
Earnings by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
Earnings History by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/18/2017Q1 2017($0.15)($0.13)$0.28 million$0.19 millionViewN/AView Earnings Details
3/31/201712/31/2016($0.14)($0.19)$0.19 million$0.26 millionViewN/AView Earnings Details
11/14/2016Q316($0.19)($0.08)$0.23 million$0.18 millionViewN/AView Earnings Details
8/16/2016Q2($0.14)($0.20)$0.27 million$0.21 millionViewN/AView Earnings Details
3/30/2016Q1($0.13)($0.17)$0.22 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Abeona Therapeutics (NASDAQ:ABEO)
2017 EPS Consensus Estimate: ($0.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.12)($0.12)($0.12)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Abeona Therapeutics (NASDAQ:ABEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Abeona Therapeutics (NASDAQ:ABEO)
Insider Ownership Percentage: 13.00%
Institutional Ownership Percentage: 17.79%
Insider Trades by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
Institutional Ownership by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
Insider Trades by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2016Todd WiderDirectorBuy5,000$5.48$27,400.00View SEC Filing  
7/31/2015Mark J AhnDirectorBuy18,182$5.50$100,001.00View SEC Filing  
1/26/2015Mark J AhnDirectorBuy25,000$4.00$100,000.00View SEC Filing  
12/24/2014Steven H RouhandehDirectorBuy250,000$4.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Abeona Therapeutics (NASDAQ:ABEO)
Latest Headlines for Abeona Therapeutics (NASDAQ:ABEO)
Source:
DateHeadline
americanbankingnews.com logoAbeona Therapeutics Inc (ABEO) PT Set at $14.00 by Maxim Group
www.americanbankingnews.com - May 25 at 8:36 PM
globenewswire.com logoAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with ... - GlobeNewswire (press release)
globenewswire.com - May 25 at 3:31 PM
finance.yahoo.com logoAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
finance.yahoo.com - May 25 at 3:31 PM
finance.yahoo.com logoAbeona Therapeutics to Present at Multiple Upcoming Conferences
finance.yahoo.com - May 19 at 9:51 AM
nasdaq.com logoAbeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights - Nasdaq
www.nasdaq.com - May 17 at 8:16 PM
americanbankingnews.com logoAbeona Therapeutics Inc (ABEO) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 17 at 11:40 AM
globenewswire.com logoAbeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights - GlobeNewswire (press release)
www.globenewswire.com - May 16 at 3:18 PM
finance.yahoo.com logoAbeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights
finance.yahoo.com - May 16 at 3:18 PM
finance.yahoo.com logoAbeona Therapeutics reports 1Q loss
finance.yahoo.com - May 16 at 3:18 PM
nasdaq.com logoAbeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT - Nasdaq
www.nasdaq.com - May 12 at 3:27 PM
americanbankingnews.com logoCantor Fitzgerald Reaffirms "Buy" Rating for Abeona Therapeutics Inc (ABEO)
www.americanbankingnews.com - May 12 at 11:40 AM
americanbankingnews.com logo$280,000.00 in Sales Expected for Abeona Therapeutics Inc (ABEO) This Quarter
www.americanbankingnews.com - May 11 at 11:50 AM
nasdaq.com logoAbeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy ... - Nasdaq
www.nasdaq.com - May 9 at 3:15 PM
reuters.com logoBRIEF-Abeona receives regulatory approval to start clinical trial in Australia
www.reuters.com - May 9 at 9:31 AM
finance.yahoo.com logoAbeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA
finance.yahoo.com - May 9 at 9:31 AM
americanbankingnews.com logoAbeona Therapeutics Inc (ABEO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 9 at 7:58 AM
americanbankingnews.com logoZacks: Analysts Anticipate Abeona Therapeutics Inc (ABEO) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - May 9 at 7:44 AM
finance.yahoo.com logoAbeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting
finance.yahoo.com - May 8 at 11:28 AM
streetinsider.com logoAbeona Therapeutics (ABEO) Provides Update from Ongoing Phase 1/2 Trial of EB-101 Gene Therapy for Severe Form ... - StreetInsider.com
www.streetinsider.com - May 2 at 3:20 PM
globenewswire.com logoAbeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the ... - GlobeNewswire (press release)
globenewswire.com - May 2 at 3:20 PM
finance.yahoo.com logoAbeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference
finance.yahoo.com - May 2 at 3:20 PM
americanbankingnews.com logoAbeona Therapeutics (ABEO) Getting Favorable Media Coverage, Report Finds
www.americanbankingnews.com - May 2 at 7:48 AM
americanbankingnews.com logoAbeona Therapeutics (ABEO) Getting Positive News Coverage, Report Finds
www.americanbankingnews.com - April 28 at 8:56 AM
americanbankingnews.com logoAbeona Therapeutics Inc (ABEO) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - April 26 at 6:46 PM
finance.yahoo.com logoETFs with exposure to Abeona Therapeutics, Inc. : April 25, 2017
finance.yahoo.com - April 26 at 5:28 AM
nasdaq.com logoAbeona Therapeutics Announces EB-101 Clinical Update to be ... - Nasdaq
www.nasdaq.com - April 25 at 3:15 PM
finance.yahoo.com logoAbeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting
finance.yahoo.com - April 25 at 3:15 PM
americanbankingnews.com logoAbeona Therapeutics (ABEO) Receives Daily News Impact Rating of 0.43
www.americanbankingnews.com - April 25 at 11:10 AM
americanbankingnews.com logoAbeona Therapeutics (ABEO) Getting Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 21 at 8:13 AM
globenewswire.com logoAbeona to Present At Multiple Upcoming Conferences - GlobeNewswire (press release)
globenewswire.com - April 20 at 3:15 PM
finance.yahoo.com logoAbeona to Present At Multiple Upcoming Conferences
finance.yahoo.com - April 20 at 3:15 PM
americanbankingnews.com logo Analysts Expect Abeona Therapeutics Inc (ABEO) Will Announce Quarterly Sales of $280,000.00
www.americanbankingnews.com - April 20 at 1:53 PM
americanbankingnews.com logoZacks: Analysts Anticipate Abeona Therapeutics Inc (ABEO) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - April 18 at 11:36 AM
americanbankingnews.com logoAbeona Therapeutics (ABEO) Getting Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 18 at 10:42 AM
americanbankingnews.com logoAbeona Therapeutics Inc (ABEO) Receives Buy Rating from Maxim Group
www.americanbankingnews.com - April 14 at 10:58 AM
americanbankingnews.com logoAbeona Therapeutics Inc (ABEO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 14 at 8:26 AM
americanbankingnews.com logoAbeona Therapeutics (ABEO) Earning Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 13 at 11:35 AM
finance.yahoo.com logoEdited Transcript of ABEO earnings conference call or presentation 10-Apr-17 2:00pm GMT
finance.yahoo.com - April 11 at 8:29 AM
seekingalpha.com logoAbeona Therapeutics' (ABEO) CEO Timothy Miller on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - April 10 at 8:17 PM
americanbankingnews.com logoAbeona Therapeutics Inc (ABEO) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 7 at 8:55 PM
finance.yahoo.com logoAbeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences
finance.yahoo.com - April 7 at 5:23 AM
finance.yahoo.com logoETFs with exposure to Abeona Therapeutics, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 5:23 AM
americanbankingnews.com logoAbeona Therapeutics' (ABEO) Buy Rating Reaffirmed at FBR & Co
www.americanbankingnews.com - April 5 at 9:12 PM
americanbankingnews.com logoAbeona Therapeutics Inc to Post FY2018 Earnings of $0.86 Per Share, FBR & Co Forecasts (ABEO)
www.americanbankingnews.com - April 5 at 3:43 PM
americanbankingnews.com logoAbeona Therapeutics Inc (ABEO) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 4 at 12:40 PM
globenewswire.com logoAbeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights - GlobeNewswire (press release)
globenewswire.com - March 31 at 3:20 PM
finance.yahoo.com logoAbeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights
finance.yahoo.com - March 31 at 3:20 PM
biz.yahoo.com logoABEONA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - March 31 at 3:20 PM
biz.yahoo.com logoABEONA THERAPEUTICS INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 30 at 8:18 PM
seekingalpha.com logoAbeona Therapeutics (ABEO) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 23 at 1:19 AM

Social

Chart

Abeona Therapeutics (ABEO) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff